Business Wire

CA-ALATION/BIGEYE/SODA

Share
Alation Forges Strategic Partnerships With Bigeye and Soda

Alation, Inc. , the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda , leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs.

Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthiness and reliability of data. This results in a streamlined analysis process that empowers data users to use data and generate insights with confidence.

“When it comes to data intelligence and data governance, Alation has long catered to the needs of every user, not just the technical user. Our customers see Alation as the primary source of reference for all metadata, which enables all teams across an organisation to make data-driven business decisions,” said Raj Gossain, Chief Product Officer, Alation. “The Alation Data Catalog is a platform known for its interoperability. With our APIs and partnerships, we continue to expand the ecosystem of companies that work with Alation, giving our customers a modern user experience that seamlessly integrates best-of-breed solutions that meet their needs.”

Fuelled by exponential data growth and expanding privacy regulations, data governance is a top priority for enterprises. Traditional approaches to data governance have long focused on restrictive data policies and procedures that hinder adoption and result in additional challenges for those responsible for the data. Effective data governance programs must focus on enabling users to leverage trusted, governed data to make informed, data-driven decisions. Organisations using an active, people-first approach to data governance, drive data culture and put quality data, not just any data, in everyone’s hands.

“A key part of ensuring data quality and reliable data pipelines is the ability to keep data teams and data consumers on the same page. With the integration between Alation and Bigeye, everyone — from data engineers all the way to business analysts — has a clear understanding of the health of the data,” said Egor Gryaznov, CTO and cofounder, Bigeye. “Pairing the leading data observability platform with Alation’s leading data catalog provides organisations with a holistic view of the quality of their data.”

“The modern data catalog is becoming a real-time, operational system that's deeply tied into an organisation’s data ecosystem. For metadata, that means it is purposefully built into every step of the data value chain, as opposed to it being an afterthought. This allows data teams to truly see what's happening so that they can catch data issues before they reach consumers downstream,” explains Maarten Masschelein, CEO and Co-Founder, Soda. “Through our partnership with Alation, users can discover and understand the data that matters to them, and trust they are working with data that is verified, reliable, and governed. Soda enables data producers and consumers to agree on what good data looks like by combining both machine learning-based alerting, as well as rules-based testing and validation of data. Every single operational metadata quality issue that Soda captures, can be made natively available in the Alation Data Catalog. We layer our data quality controls on top of Alation’s automated lineage to make it easy to do Root Cause Analysis (RCA), as well as assess the upstream and downstream impact of a data issue.”

To learn more about Alation’s partnerships with Bigeye and Soda:

About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 300 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com .

About Bigeye
Bigeye is the leading data observability platform designed to help data teams build trust in data. Data teams use Bigeye to instrument their data with monitoring, detect anomalies, and publish SLAs for their stakeholders to know the health of the data at all times and ensure reliable data pipelines. Complete API access, a user-friendly interface, and flexible customisation options help data teams work the way they want to. Bigeye can be deployed in as little as 15 minutes and uses automation and anomaly detection to help teams monitor all aspects of their data quality, proactively detect and resolve issues, and ensure that every user can trust the data. www.bigeye.com

About Soda
Soda is the data monitoring platform that keeps your data fit for purpose, verifiable and trustworthy. We uncover data issues, alert the right teams, and trigger resolution workflows to identify causes that impede data quality. Our open source testing projects and monitoring platform brings together data engineers, operations and the business to create trusted data. Data-driven organisations choose Soda to realise the value of their data and secure its quality. For more information, visit www.soda.io .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release

Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye